全文获取类型
收费全文 | 988篇 |
免费 | 38篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 39篇 |
妇产科学 | 10篇 |
基础医学 | 86篇 |
口腔科学 | 22篇 |
临床医学 | 87篇 |
内科学 | 203篇 |
皮肤病学 | 9篇 |
神经病学 | 70篇 |
特种医学 | 173篇 |
外科学 | 65篇 |
综合类 | 17篇 |
预防医学 | 25篇 |
眼科学 | 9篇 |
药学 | 60篇 |
肿瘤学 | 189篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 16篇 |
2017年 | 8篇 |
2016年 | 6篇 |
2015年 | 18篇 |
2014年 | 18篇 |
2013年 | 16篇 |
2012年 | 21篇 |
2011年 | 28篇 |
2010年 | 32篇 |
2009年 | 41篇 |
2008年 | 25篇 |
2007年 | 59篇 |
2006年 | 25篇 |
2005年 | 26篇 |
2004年 | 25篇 |
2003年 | 30篇 |
2002年 | 24篇 |
2001年 | 29篇 |
2000年 | 31篇 |
1999年 | 26篇 |
1998年 | 59篇 |
1997年 | 48篇 |
1996年 | 44篇 |
1995年 | 32篇 |
1994年 | 26篇 |
1993年 | 35篇 |
1992年 | 21篇 |
1991年 | 19篇 |
1990年 | 17篇 |
1989年 | 32篇 |
1988年 | 21篇 |
1987年 | 28篇 |
1986年 | 15篇 |
1985年 | 21篇 |
1984年 | 17篇 |
1983年 | 16篇 |
1982年 | 14篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1979年 | 6篇 |
1978年 | 9篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1973年 | 3篇 |
排序方式: 共有1065条查询结果,搜索用时 31 毫秒
71.
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients 总被引:24,自引:0,他引:24
Foekens JA Peters HA Look MP Portengen H Schmitt M Kramer MD Brünner N Jänicke F Meijer-van Gelder ME Henzen-Logmans SC van Putten WL Klijn JG 《Cancer research》2000,60(3):636-643
The antigen levels of components of the urokinase-type plasminogen activator (uPA) system of plasminogen activation are correlated with prognosis in several types of cancers, including breast cancer. In the present study involving 2780 patients with primary invasive breast cancer, we have evaluated the prognostic importance of the four major components of the uPA system [uPA, the receptor uPAR (CD87), and the inhibitors PAI-1 and PAI-2]. The antigen levels were determined by ELISA in cytosols prepared from primary breast tumors. The levels of the four factors significantly correlated with each other; the Spearman rank correlation coefficients (r(s)) ranged from 0.32 (between PAI-2 and PAI-1 or uPAR) to 0.59 (between uPA and PAI-1). The median duration of follow-up of patients still alive was 88 months. In the multivariate analyses for relapse-free survival (RFS) and overall survival (OS), we defined a basic model including age, menopausal status, tumor size and grade, lymph node status, adjuvant therapy, and steroid hormone receptor status. uPA, uPAR, PAI-1, and PAI-2 were considered as categorical variables, each with two cut points that were established by isotonic regression analysis. Compared with tumors with low levels, those with intermediate and high levels showed a relative hazard rate (RHR) and 95% confidence interval (95% CI) of 1.22 (1.02-1.45) and 1.69 (1.39-2.05) for uPA, and 1.32 (1.14-1.54) and 2.17 (1.74-2.70) for PAI-1, respectively, in multivariate analysis for RFS in all patients. Compared with tumors with high PAI-2 levels, those with intermediate and low levels showed a poor RFS with a RHR (95% CI) of 1.30 (1.14-1.48) and 1.76 (1.38-2.24), respectively. Similar results were obtained in the multivariate analysis for OS in all patients. Furthermore, uPA and PAI-1 were independent predictive factors of a poor RFS and OS in node-negative and node-positive patients. PAI-2 also added to the multivariate models for RFS in node-negative and node-positive patients, and in the analysis for OS in node-negative patients. uPAR did not further contribute to any of the multivariate models. A prognostic score was calculated based on the estimates from the final multivariate model for RFS. Using this score, the difference between the highest and lowest 10% risk groups was 66% in the analysis for RFS at 10 years and 61% in the analysis for OS. Moreover, separate prognostic scores were calculated for node-negative and node-positive patients. In the 10% highest risk groups, the proportion of disease-free patients was only 27 +/- 6% and 9 +/- 3% at 10 years for node-negative and node-positive patients, respectively. These proportions were 86 +/- 4% and 61 +/- 6% for the corresponding 10% lowest risk groups of relapse. We conclude that several components of the uPA system are potential predictors of RFS and OS in patients with primary invasive breast cancer. Knowledge of these factors could be helpful to assess the individual risk of patients, to select various types of adjuvant treatment and to identify patients who may benefit from targeted therapies that are currently being developed. 相似文献
72.
73.
74.
J C Reubi U Horisberger C E Essed J Jeekel J G Klijn S W Lamberts 《Gastroenterology》1988,95(3):760-763
Somatostatin receptor frequency was evaluated in 12 human exocrine pancreatic carcinomas taken after surgery. The tumors were analyzed by receptor autoradiography on tissue sections and by in vitro binding techniques on tumor homogenates. None of the tested human pancreatic carcinomas was shown to possess specific somatostatin receptors. In comparison, five single tumors taken from rats transplanted with the rat pancreatic adenocarcinoma CA 20948 were found to contain specific high-affinity somatostatin receptors. Also, human endocrine pancreatic tumors, i.e., two insulinomas, did contain somatostatin receptors under identical experimental conditions. These data confirm previous results with other tumors, documenting the absence of somatostatin receptors in highly malignant human carcinomas. They also may represent an explantation at the molecular level for the lack of therapeutic effect of somatostatin analogues such as SMS 201-995 seen in patients with advanced exocrine pancreatic carcinomas. 相似文献
75.
Wooden foreign bodies in soft tissue: detection at US 总被引:4,自引:0,他引:4
76.
Emphysema in the renal allograft 总被引:1,自引:0,他引:1
Two diabetic patients in whom emphysematous pyelonephritis developed after renal transplantation are described. Clinical recognition of this unusual and serious infection is masked by the effects of immunosuppression. Abdominal radiographic, ultrasound, and computed tomography findings are discussed. The clinical presentation includes urinary tract infection, sepsis, and acute tubular malfunction of the allograft in insulin-dependent diabetics. 相似文献
77.
J Alexieva-Figusch W L Van Putten H A van Gilse J Blonk-vd Wijst J G Klijn 《Medical oncology and tumor pharmacotherapy》1985,2(2):69-75
The progestin megestrol acetate and the anti-estrogen tamoxifen are used as effective drugs in the treatment of metastatic breast cancer and have few side effects. The sequence and indications for use in practice still need to be defined. Of 219 postmenopausal patients with metastatic breast cancer and measurable lesions, 136 were treated with megestrol acetate (MA) per os (180 mg daily) and followed by tamoxifen (TAM) (40 mg daily) in cases with progression, and 83 patients were treated with the inverse drug regimen. In the first line treatment they showed similar effects: MA caused remission in 31/136 patients (23%) and TAM in 17/80 patients (22%) (mean duration 12 and 13 months respectively), while as a second treatment line MA caused remission in 14/83 patients (17%) and TAM in 12/132 patients (9%), which was not significant (P = 0.10). Also with respect to survival there was no significant difference between the two treatment modalities. 相似文献
78.
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer 总被引:3,自引:0,他引:3
A variety of serine proteases, including urokinase-type plasminogen activator (uPA), plasmin,and polymorphonuclear leukocyte elastase (PMN-E), have been implicated in the processes of tumor cell invasion and metastasis. Besides degrading of matrix proteins, PMN-E has been shown to be able to cleave and inactivate plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of uPA, and alpha2-antiplasmin, the natural inhibitor of plasmin, thus enabling an uncontrolled matrix degradation by the fibrinolytic enzymes. Because only limited data are available on a relationship between the tumor level of PMN-E and prognosis in primary breast cancer patients, in the present study we have measured with an ELISA the levels of PMN-E (in complex with alpha1-proteinase inhibitor) in cytosolic extracts of 1143 primary breast tumors. Levels of complexed PMN-E have been correlated with the lengths of metastasis-free survival (MFS), relapse-free survival, and overall survival, and a comparison was made with data previously obtained for uPA and PAI-1. Our results show that patients with a high PMN-E level in their primary tumor had a rapid relapse and an early death compared with patients with a low tumor level of PMN-E. This held true for node-negative and node-positive subgroups of patients as well. The relationship of PMN-E with a poor prognosis was especially obvious during short-term follow-up (0-60 months). In Cox multivariate regression analysis, corrected for the traditional prognostic factors, PMN-E was an independent prognostic factor, and high levels of PMN-E were associated with a poor MFS [hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.23-2.16; P < 0.001], relapse-free survival (HR, 1.45; 95% CI, 1.10-1.89; P = 0.01), and overall survival (HR, 1.64; 95% CI, 1.20-2.23; P = 0.003). Furthermore, in all three multivariate models, PMN-E still added significantly to the model after the additional inclusion of the uPA. PMN-E was an independent prognostic factor for MFS even in the multivariate analysis including the traditional clinical prognostic factors and the strong established biochemical prognostic factors uPA and PAI-1. Our present study suggests that PMN-E is associated with breast cancer metastasis, and knowledge of the tumor PMN-E status might be helpful in selecting the appropriate individualized (adjuvant) treatment for patients with breast cancer. 相似文献
79.
Harkes IC Elstrodt F Dinjens WN Molier M Klijn JG Berns EM Schutte M 《British journal of cancer》2003,89(12):2289-2292
Heterozygous loss of relatively large chromosomal regions is a hallmark of the inactivation of tumour suppressor genes. Searching for deletions in cancer genomes therefore provides an attractive option to identify new tumour suppressor genes. Here, we have performed a genome-wide survey for regions exhibiting allelic loss in 24 commercially available breast cancer cell lines and four breast cancer xenografts, using microsatellite analysis. The assembled allelotype revealed an average fractional allelic loss of 0.34. A total of 19 arms had low allelic loss frequencies (<25%) and 17 arms had moderate allelic loss frequencies (25-50%). Five chromosomal arms were deleted in more than half of the breast cancer samples (8p, 10q, 13q, 17p, and 17q). Three of these frequently lost chromosomal arms had not been identified as such by comparative genome hybridisation, illustrating the higher sensitivity of microsatellite analysis for the detection of allelic losses. As we present allelic loss data of individual samples, our allelotype should not only aid the identification of new breast cancer genes but also provides a baseline for myriad studies involving these breast cancer cell lines. 相似文献
80.
Cognitive impairment in patients
with carotid artery occlusion and ipsilateral transient ischemic
attacks 总被引:3,自引:0,他引:3
Bakker FC Klijn CJ Jennekens-Schinkel A van der Tweel I Tulleken CA Kappelle LJ 《Journal of neurology》2003,250(11):1340-1347
Abstract.
Although transient ischemic attacks (TIAs) by definition
do not cause lasting neurological deficits, cognitive impairment
has been suggested in patients with carotid artery disease who
have suffered from a TIA. The purpose of our study was to assess
whether patients with carotid artery disease and TIAs are
cognitively impaired, to describe the frequency, nature and
severity of this impairment, and to search for associated
patient characteristics.Thirty-nine consecutive patients with carotid occlusion
and ipsilateral cerebral or retinal TIAs, and 46 healthy
controls underwent extensive neuropsychological assessment.
Performances were compared group-wise with analysis of variance.
In addition, the presence of cognitive impairment in the
individual patient was determined. Associations between illness
characteristics and cognitive impairment were explored with
regression analysis.Fifty-four percent of patients were cognitively impaired.
Cognitive deficits were non-specific in nature and mild in
severity. Impairment occurred also in patients with isolated
retinal symptoms and in those without visible ischemic brain
lesions on MRI. Neither the presence of any vascular risk
factor, the side of the symptomatic carotid occlusion, the uni-
or bilaterality of carotid occlusion, nor the number of cerebral
ischemic lesions were predictors of cognitive impairment.We conclude that about half of the patients with carotid
artery occlusion and ipsilateral TIAs are cognitively impaired.
The presence of cognitive deficits in patients with isolated
retinal symptoms and in those without cerebral ischemic lesions
on MRI argues against an exclusive role for structural brain
damage in the pathogenesis of these deficits. 相似文献